In this scenario, the reported association between CDK12 oncogenic function and pathological SGOC regulation is a paradigm of how a deeper understanding of the metabolic vulnerabilities specifically underlying the process of malignant transformation by a given oncogene may aid accurate biomarker-based patient stratification for the selection of targeted anti-cancer therapies. This evidence concerns the gene CDK12 and cancer.